Alaunos Therapeutics Inc. stocks have been trading up by 16.68 percent amid heightened optimism over its latest oncology pipeline developments.
Click Here for a Millionaire's POV on Trading TCRT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Alaunos Therapeutics completed the acquisition of Velaris Therapeutics, adding a pipeline focused on pulmonary arterial hypertension and related cardiopulmonary diseases.
- Alongside the deal, Alaunos raised about $350M in Series C non‑voting convertible preferred stock, extending its cash runway into 2029.
- After the acquisition and financing, TCRT shares exploded higher, with reports flagging roughly 126% to ~225% gains on extremely heavy trading volume.
- The new capital backs development of lead Velaris asset VLR199 and several other candidates through proof‑of‑concept and early regulatory steps.
- Shares popped another ~35% after filings showed Fairmount Funds took a 19.99% stake in Alaunos and is seeking four of five board seats.
Live Update At 09:17:20 EDT: On Monday, October 19, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 16.68%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TCRT has been trading like a biotech on steroids. In late September, Alaunos Therapeutics sat under $1, closing around $0.89–$1.05. By 2026/10/13, after the Velaris Therapeutics acquisition and $350M private placement headlines hit, TCRT ripped from $1.73 to a $4.32 high before closing at $3.03. That is a full-blown re‑rating in a single session.
The follow‑through has been choppy but still elevated. TCRT closed at $2.63 on 2026/10/16 after a wild two‑day rollercoaster between $1.80 and $4.40. Intraday 5‑minute data shows persistent volatility, with pre‑market spikes above $3.50, quick flushes toward $2.80, and repeated bounces near $3.00. This is the textbook profile of a momentum trader’s playground.
More Breaking News
- SKYD Stock Slides As Legal Drama And Debt Moves Rattle Traders
- EOG Resources Stock Rises As Analysts Hike Price Targets
- Alcoa Stock Rises As Earnings Beat Fuels Bullish Turn
- SOFI Stock Slips As Price Target Cut Adds $1B Headwind Warning
Under the hood, Alaunos is still a classic early‑stage biotech. Revenue is just $5,000, pretax margins are deeply negative, and return on equity is massively below zero. The balance sheet before the raise showed only $124,000 in cash, a current ratio of 0.8, and negative working capital. That’s exactly why the $350M financing matters: it transforms TCRT from a cash‑starved story into a multi‑year runway name, at least on paper, while traders lean into the volatility.
Why Traders Are Watching TCRT Now
TCRT did not just drift higher; it detonated. The catalyst was Alaunos Therapeutics closing its Velaris Therapeutics acquisition and locking in a $350M private placement. That one‑two punch changed the narrative overnight. Instead of a tiny oncology‑focused micro‑cap scraping by, traders now see a retooled cardiopulmonary platform with funding visibility into 2029.
The Velaris deal hands Alaunos a pipeline of ActRII‑Fc ligand traps and biologics aimed at pulmonary arterial hypertension and similar cardiopulmonary conditions. That is a very different story than the legacy assets most traders associated with TCRT. Lead candidate VLR199 now sits front and center, with management signaling enough capital to push it, and other programs, through proof‑of‑concept and initial regulatory filings. For momentum traders, a clear flagship drug plus a full war chest often means one thing: sustained speculation.
The price action confirms it. Reports of 126% to roughly 225% single‑day gains in TCRT, on extremely heavy trading volume, scream “re‑pricing” rather than a casual bounce. When a stock more than doubles while liquidity explodes, it tells you a lot of new money just discovered the name. That theme continued when SEC filings showed Fairmount Funds scooping up 19.99% of Alaunos Therapeutics and aiming for four out of five board seats. The stock jumped another 35% on that governance twist.
Active traders read that Fairmount move as a serious vote of confidence and a potential shake‑up signal. Almost 20% ownership plus a bid for board control is not passive. It suggests tighter execution and a sharper focus on value creation around the Velaris assets. Put it together, and TCRT now sits at the intersection of fresh capital, a new therapeutic direction, and activist‑style oversight — a powerful cocktail for ongoing volatility.
Conclusion
For traders, TCRT is a live case study in how quickly a beaten‑down biotech can flip its script. Days ago, Alaunos Therapeutics looked like a company with minimal revenue, negative working capital, and a shrinking cash pile. Today, the same ticker is trading entirely on a new storyline: a Velaris‑driven cardiopulmonary pipeline, a $350M capital infusion, and an activist‑leaning holder in Fairmount Funds pushing for four of five board seats.
That does not erase the risks. Alaunos still has no meaningful commercial revenue, operates with highly negative returns on capital, and must execute across complex clinical and regulatory paths for VLR199 and its other ligands. The pretax margin numbers remind traders that this is a cash‑burning R&D engine, not a steady earner. Any clinical stumble or regulatory delay can unwind a big part of this recent move in TCRT.
But momentum is momentum. TCRT has become a high‑beta trading vehicle where news flow, filings, and clinical updates can trigger outsized swings both ways. This makes risk management absolutely critical. As Tim Sykes likes to say, “The best traders aren’t the ones who find the hottest stocks, they’re the ones who cut losses the fastest when the hot stock turns cold.” And as Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” For anyone tracking Alaunos Therapeutics now, that mindset matters as much as any chart pattern or press release. This coverage is for educational and research purposes only, and every trader needs to do their own homework before entering the TCRT arena.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.